MDS Podcast

Dr. Anna Latorre is interviewed by Dr. Sara Schaefer about her study exploring the role of transcutaneous spinal cord simulation for suppression of postural tremor in essential tremor, including the potential pathophysiological mechanisms and implications for therapeutic use. Journal CME is available until October 21, 2025 Read the article.

In the introductory episode for the Tremor Special Series, Dr. Elan Louis tells us about the epidemiology of tremor as well as patients' and health care providers' awareness (or lack thereof). He guides us through his journey from when his mentor suggested that he'd look into familial essential tremor to the most important discoveries of the last two decades. Finally he gives us a glimpse of what's about to come and why tremor matters.

Prof. Alessio Di Fonzo, Director of the Movement Disorders Unit in Milano, discusses his award-winning research on harmonizing genetic testing for early-onset Parkinson's disease. He highlights challenges in interpreting genetic variants and the need for continuous updates in classification. Di Fonzo emphasizes the prevalence of GBA1 mutations in patients diagnosed before 40 and the importance of collaborative networks among health institutes. His insights aim to improve patient care through unified genetic interpretation and enhanced diagnostic techniques.

Dr. Hannah E. Reese and Mr. W. Alan Brown discuss their pilot study of a mindfulness-based group virtual intervention for tic disorders, that was co-developed with patients. Journal CME is available until August 21, 2025 Read the article.

Dr. Alexander Lehn, a neurologist at Princess Alexandria Hospital in Brisbane, dives into functional movement disorders, shedding light on brain activity and risk factors. He discusses the critical aspects of building specialized clinics and the importance of thorough patient histories. The conversation highlights predictive coding and its role in recovery, along with ongoing research from the Functional Movement Disorder Study Group. Lehn also examines evolving medical perspectives on these disorders, emphasizing advancements in treatment and the significance of patient communication.

Prof. Brit Mollenhauer, Chair of the Movement Disorders Hospital in Germany, dives into the world of biomarker research and its impact on neurodegenerative diseases. She emphasizes the importance of collaboration between clinicians and basic scientists, arguing that MDS's diversity can enhance innovation. The discussion touches on how environmental factors and climate change relate to these diseases. Mollenhauer also explores the multifunctional role of alpha-synuclein, revealing its intriguing potential beyond just neurodegeneration.

Michael Zer, a professor at the Technical University of Munich and an expert in gene discovery, dives into the fascinating world of genetic dystonias. He discusses groundbreaking advancements in identifying dystonia-related genes using next-generation sequencing. The conversation uncovers critical molecular pathways that play a role in the condition, such as the integrated stress response. Zer also emphasizes the potential for translating these discoveries into effective treatments, highlighting the links between dystonia and neurodevelopmental disorders.

Dr. Aesef Shaikh, a neurology professor and co-chair of the MDS Tremor Study Group, dives into groundbreaking advancements in tremor research. He highlights how technology like machine learning can refine treatment personalization. The conversation shifts to viewing tremors as network disorders, emphasizing the crucial role of dentitorubrothalamic fibers. They examine the tremor-dystonia continuum, advocating for a nuanced understanding rather than rigid classifications. Dr. Shaikh underscores the need for ongoing research to unlock complexities in these movement disorders.

Dr. Kishore Kumar, a neurologist and movement disorder specialist from Australia, dives into groundbreaking genetic discoveries linked to Parkinson's disease, dystonia, and ataxia. He details how innovative technologies like long-read sequencing can unveil new genes and epigenetic changes driving these disorders. The conversation highlights the significance of such advancements in improving diagnoses and treatments for patients, as well as the importance of ongoing research and better access to genetic testing.

Victor Fung, the President of the International Parkinson and Movement Disorder Society, discusses his vision for equality in healthcare access and amplifying patient engagement. He shares insights on eliminating disparities in treatment globally and emphasizes the importance of diverse voices in organizational activities. The conversation delves into redefining Parkinson’s disease by integrating clinical and biological perspectives. Fung also outlines strategic initiatives for the future of movement disorders, highlighting plans for a major meeting in 2025.